BioNTech to Buy FDA Priority Review Voucher From Scholar Rock for $205 Million

Bitget2026/11/10 12:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioNTech agreed today to acquire a US FDA Priority Review Voucher from Scholar Rock for $205 million in cash.
The voucher will support a future filing for a late-stage oncology asset, shortening the target FDA review timeline.
Closing remains subject to customary conditions, including US antitrust clearance under the Hart-Scott-Rodino Act.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001776985-26-000083), on November 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioNTech to Buy FDA Priority Review Voucher From Scholar Rock for $205 Million

You may also like

Crypto prices